Loading...

ALDX ALDEYRA THERAPEUTICS INC Management Changes 8-K Filing

LDYR

LDX

ALDEYRA THERAPEUTICS INC

(ALDX)

2025 8-K

FDA Response Received

Management Change

FDA Deadline Extension

Webcast Announcement

Positive Trial Results

FDA Fast Track Approval

New Product Launches

Special Protocol Assessment

New Product Launches

Clinical Trials

Board Appointment

Collaboration Update

Drug Application Resubmission

Loan Agreement Amendment

Management Changes

Open Market Sale Agreement

Slide Presentation at Resea...

Regulation FD Disclosure

Regulation FD Disclosure

Extension of Option Agreement

FDA Update on Drug Candidat...

Option Agreement with AbbVie

FDA Review Issues

Appointments, Changes in Ma...

FDA Response Letter

FDA Inspection Announcement

Financial Results and Corpo...

Regulation FD Disclosure

FDA Accepts NDA for ADX 2191

FDA Accepts NDA for Reproxalap

External Links:

Stephen G. Machatha, Ph.D. resigned as Chief Development Officer of Aldeyra Therapeutics effective before March 31, 2026, with a transition period and compensation totaling $176,000, which includes his 2025 bonus.

AI Assistant

ALDEYRA THERAPEUTICS INC

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.